TY - JOUR
T1 - Recommendations for the use of CanRisk for tubo-ovarian cancer risk estimation
T2 - a focus group and Research ANd Development-modified Delphi-based study
AU - Gootzen, Tamar A.
AU - Schauwaert, Jolijn
AU - Steenbeek, Miranda P.
AU - van Altena, Anne M.
AU - de Hullu, Joanne A.
AU - Kets, C. Marleen
AU - Hermens, Rosella P.M.G.
AU - CanRisk, Unknown
AU - Aalfs, Cora M.
AU - Apperloo, Mirjam
AU - van de Beek, Irma
AU - Collee, Margriet
AU - Gaarenstroom, Katja N.
AU - Gomez-Garcia, Encarna B.
AU - Hulshoff, Anneke
AU - de Jong, Mirjam F.C.
AU - Piek, Jurgen M.J.
AU - Reesink-Peeters, Nathalie
AU - Schuurs-Hoeijmakers, Janneke H.M.
AU - Verhoef, Senno
AU - Yigit, Refika
N1 - Publisher Copyright:
Copyright © 2026 The Author(s). Published by Wolters Kluwer Health, Inc.
PY - 2026/5
Y1 - 2026/5
N2 - CanRisk is a risk prediction tool used to estimate tubo-ovarian cancer risk. It is increasingly being used in clinical practice. However, guidelines regarding the use of the CanRisk tool in clinical practice are lacking. Therefore, we aim to identify recommendations for the use of CanRisk in clinical practice. First, we organized separate focus group interviews with clinical genetic healthcare providers, gynecologic–oncology healthcare providers, patients, and patient advocates to identify relevant themes and subthemes regarding the use of CanRisk. Subsequently, we followed a Research ANd Development-modified Delphi-based approach using a questionnaire round consisting of statements based on previously identified themes, followed by a consensus meeting. Statements with consensus were transferred into recommendations and sent for approval to all participants who completed the questionnaire. We identified 44 statements based on the focus group meetings. Consensus was reached on 19 statements, of which 17 were transferred to recommendations. They concerned CanRisk itself (n = 3), counseling (n = 4), indications for the use of CanRisk (n = 2), data entry into CanRisk (n = 3), decisions regarding risk-reducing surgery and CanRisk (n = 2), education (n = 1), and collaboration regarding CanRisk (n = 4). Recommendations included that clinical geneticists should use CanRisk and communicate results to the gynecologic oncologist. Furthermore, the CanRisk result should not be used as an absolute threshold for risk-reducing surgery eligibility. This research identified recommendations for the use of CanRisk in clinical practice to standardize and optimize tubo-ovarian cancer prevention. CanRisk was seen as a valuable addition to healthcare that should be used in a uniform manner.
AB - CanRisk is a risk prediction tool used to estimate tubo-ovarian cancer risk. It is increasingly being used in clinical practice. However, guidelines regarding the use of the CanRisk tool in clinical practice are lacking. Therefore, we aim to identify recommendations for the use of CanRisk in clinical practice. First, we organized separate focus group interviews with clinical genetic healthcare providers, gynecologic–oncology healthcare providers, patients, and patient advocates to identify relevant themes and subthemes regarding the use of CanRisk. Subsequently, we followed a Research ANd Development-modified Delphi-based approach using a questionnaire round consisting of statements based on previously identified themes, followed by a consensus meeting. Statements with consensus were transferred into recommendations and sent for approval to all participants who completed the questionnaire. We identified 44 statements based on the focus group meetings. Consensus was reached on 19 statements, of which 17 were transferred to recommendations. They concerned CanRisk itself (n = 3), counseling (n = 4), indications for the use of CanRisk (n = 2), data entry into CanRisk (n = 3), decisions regarding risk-reducing surgery and CanRisk (n = 2), education (n = 1), and collaboration regarding CanRisk (n = 4). Recommendations included that clinical geneticists should use CanRisk and communicate results to the gynecologic oncologist. Furthermore, the CanRisk result should not be used as an absolute threshold for risk-reducing surgery eligibility. This research identified recommendations for the use of CanRisk in clinical practice to standardize and optimize tubo-ovarian cancer prevention. CanRisk was seen as a valuable addition to healthcare that should be used in a uniform manner.
KW - cancer genetics
KW - CanRisk
KW - ovarian cancer
KW - prevention
KW - risk estimation
U2 - 10.1097/CEJ.0000000000001024
DO - 10.1097/CEJ.0000000000001024
M3 - Article
SN - 0959-8278
JO - European Journal of Cancer Prevention
JF - European Journal of Cancer Prevention
ER -